Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and MyD88 L265P Mutation - Regional Cancer Care Associates LLC

Clinical Trials

Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and MyD88 L265P Mutation

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Idera
Protocol Number
Idera 8400-402
Cancer Diagnosis
To Learn More Call
201-510-0910